Please assess the completion status of the following clinical trial:

Trial Title: Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory, postmenopausal women, aged ≥ 55 to ≤ 85~* Low BMD measured by dual energy X-ray absorptiometry (DXA) and assessed by the central imaging vendor (equivalent to T-scores between -2.0 and -3.5)~Exclusion Criteria:~* History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or pelvis after age 50~* Untreated hyper- or hypothyroidism~* Current hyper- or hypoparathyroidism, hypo- or hypercalcemia~* Elevated transaminases~* Significantly impaired renal function~* Positive for: human immunodeficiency virus (HIV), hepatitis-C or hepatitis-B surface antigen~* Malignancy~* History of solid organ or bone marrow transplants~* Use of agents affecting bone metabolism~* Contraindicated or intolerant of alendronate therapy~* Contraindicated or intolerant of teriparatide therapy~Inclusion Criteria for the 12 month extension phase (Month 24 to 36):~- Normocalcemia at or after the Month 21 visit but before the Month 24 study visit~Exclusion Criteria for the 12 month extension phase (Month 24 to 36)~* Incidence of a clinical vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis during the initial 24 month treatment phase of the study~* A BMD loss of ≥ 7.0% from baseline at any time up to the Month 18 visit of the initial 24-month treatment phase~* Malignancy~* History of osteonecrosis of the jaw~* Use of proscribed medication during the initial 24 month treatment phase~* Contraindicated or intolerant of denosumab therapy~Inclusion Criteria for the 12 month re-treatment phase (Month 36 to 48)~* Albumin adjusted serum calcium of the most recent blood draw at or after the Month 30 visit but before the Month 36 study visit. Calcium repletion is permitted and central laboratory analysis of albumin adjusted serum calcium may be repeated before the Month 36 study visit~* Participation in Group A or B during initial 24 month treatment phase~* Subject has reached M36 of the study~* Appropriate written informed consent must be obtained~Exclusion Criteria for the 12 month re-treatment phase (Month 36 to 48)~* New malignancy~* Use of proscribed medication during the 12 month extension phase~Inclusion Criteria for the 24 month follow-on phase (Month 48 to 72) General inclusion criteria for participation~* Subject has reached month 48 of the study~* Appropriate written informed consent must be obtained Inclusion criteria for assignment to the no intervention group~* During the 24 month AMG 785 treatment phase, subject was assigned to any AMG 785 treatment group~* During the 12 month denosumab extension phase, subject was assigned to the denosumab treatment group Exclusion for the 24 month follow-on phase (Month 48 to 72)~* New malignancy~* Use of proscribed meds during the 12 month re-treatment phase~* Partial informed consent withdrawal and discontinuation of investigational product at any time up to month 48 visit~* Incidence of a clinical vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis during the initial 24 month treatment phase of the study~* BMD T-score of ≤ -2.5 at the lumbar spine, total hip, or femoral neck based on local read of the DXA scans at month 48~* Intolerance to zoledronic acid

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously (SC) for up to 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
- Alendronate (Type: ACTIVE_COMPARATOR): Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. At month 36 participants ended study participation.
- Teriparatide (Type: ACTIVE_COMPARATOR): Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
- Romosozumab 70 mg QM (Type: EXPERIMENTAL): Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
- Romosozumab 140 mg Q3M (Type: EXPERIMENTAL): Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
- Romosozumab 140 mg QM (Type: EXPERIMENTAL): Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
- Romosozumab 210 mg Q3M (Type: EXPERIMENTAL): Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.
- Romosozumab 210 mg QM (Type: EXPERIMENTAL): Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete